What drug to buy? generic brand substitution in base of the pyramid markets: Evidence from Ghana

Abstract

Prescription brand substitution also known as generic substitution (GS)is a worldwide phenomenon. In the pharmaceutical industry, growth of the generic drug market implies growth in the number and types of substitutes for ethical (innovator) pharmaceutical products. This threat is relevant mainly due to the comparatively lower prices of these substitutes. Ultimately, prescription brand substitution renders the various marketing efforts and investments of the affected pharmaceutical companies fruitless. The efforts in the literature have focused more on cost as the reason but there seems to be more reasons than cost in developing countries like Ghana. The study examined the marketing-related impacts of prescription brand substitution at community pharmacies in Ghana. Utilizing the ideas of Porter’s five competitive forces model, specifically the threat of substitute products and services, the study which is cross-sectional, deductive and descriptive survey in nature, used a mix of cluster sampling and purposive sampling to arrive at a final sample size of 50 pharmacies and 9 pharmaceutical companies,. Data collected were analysed using simple linear regression and descriptive statistics. Weak but statistically significant relationship between frequency of pharmacy calls and nature of drug substitution was observed. Also, prescription brand substitution is prevalent at community pharmacies in Ghana, and that ethical companies are the most affected. Pharmacy front line staff and patients played contributory roles in this phenomenon. It is recommended that Ethical pharmaceutical companies should acknowledge, plan and act in order to minimize the competitive effects of prescription brand substitution

Keywords

Get full access to this article

View all access options for this article.

References

Poku-Bonsu

. An examination of the marketing-related impacts of prescription brand substitution at community pharmacies in Ghana. Master’s thesis, Ghana: University of Applied Management, 2014.

Kotler

Levy

. Broadening the concept of marketing. J Marketing 1969; 33: 10–15.

Basheer

Tareq

. Bridging the gap between R & D – Marketing in the pharmaceutical industry in Malaysia, J Modern Marketing Research 2012; 1(2), 74–78.

Hellström

Niklas

. Side effects of generic competition? The Eur J Health Econ 2004; 5(3): 203–208.

World Medical Association . Ethical principles for medical research involving human subjects. In: Report: 59th Assembly World Medical Association Declaration of Helsinki, October, 2008, Seoul, Republic of Korea.

Porter

. Competitive Advantage: Creating and Sustaining Superior Performance. Free Press, 1998.

Timonen

Bengtström

Karttunen

, et al. The impact of generic substitution on the activities of pharmaceutical companies - a survey from the companies’ perspective one year and five years after the introduction of generic substitution in Finland. BMC Clin Pharmacology 2010; 10: 15.

World Medical Association . World Medical Association: Statement on Drug Substitution – World Medical Association. World Medical Association, 2013. http://seminarprojects.com/Thread-marketing-strategies-work-by-different-pharmaceutical-companies

Butler

Alexander

Becoming customer of choice in the healthcare supply chain. In Aust and New Zealand Marketing Academy Conference 2011, Perth, WA: School of Marketing, Edith Cowan University, 2011.

10.

Hubbard

Beamish

. Strategic Management, Thinking, analysis and action. 4th edition Pearson Education AU, 2011.

11.

Keat

Young

. Managerial Economics, Economic Tools for Today’s Decision Makers, 6th edition, Prentice-Hall, 2009.

12.

Porter

. Competitive advantage: creating and Sustaining Superior Performance. Free Press, 1980.

13.

Carter

. The geopolitics of diaspora. Royal geographical Association 2005; 37: 54–63.

14.

Porter

. Competitive advantage: creating and Sustaining Superior Performance. Free Press. 2001.

15.

Barney

Hansen

. Trustworthiness as a source of competitive advantage, Strateg Management J 2006; 15: 175–190.

16.

Brennan

Distler

Hinman

, et al. A Human Rights approach to Intellectual Property and Access to Medicine: Global Health Justice Policy Paper 1, Yale Law School and Yale School of Public Health, 2013.

17.

Manchanda

Dick

Ching

, et al. Understanding firm, physician and consumer choice behavior in the pharmaceutical industry. Marketing Lett 2005; 16(3/4): 293–308.

18.

Kremer

Levy

. Peer effects and alcohol use among college students. J Econ Perspect 2008; 22(3): 189–206.

19.

Narayanan

Manchanda

Chintagunta

. Temporal differences in the role of marketing communication in new product categories. J Marketing Res 2005; 42: 278–290.

20.

Kotler

Amstrong

. Principles of Marketing. 15th edition, Global edition, Pearson Publishers, 2013.

21.

Data monitor research store . Pharmaceutical Marketing. Data Monitor Research Store, 2001. http://www.datamonitor.com/store/News/

22.

Smith

. New globalism, new urbanism: gentrification as global urban strategy, A Radic J Geogr 2002; 34: 427–450.

23.

Fetal Alcohol Syndrome Act of (1995) . Substitute Senate Bill 5688, State of Washington, 54th Legislature, Blackwell Publishing Ltd, 1995.

24.

DiMasi

Grabowski

. The cost of biopharmaceutical R&D: is biotech different? MDE Manage Decis Econ. 2007; 28(4–5): 469–479.

25.

Gill

. Historical materialism and international relations. In: Index, Digital Paperback Reprint Edition. Cambridge, MA: Cambridge University Press, 2010.

26.

Bahari

Hassan

. Kleine levin syndrome in malaysia: first typical case, BMJ Case Rep 2007; 2012: bcr0820114679.

27.

Schommer

Wiederholt

. The association of prescription status, patient age, patient gender, and patient question asking behavior with the content of pharmacist-patient communication, Pharm Res 1997; 14(2): 145–151.

28.

Norgaard

. Functional differences in yeast protein disulfide isomerases. J Cell Biol 2001; 152(3):553–562.

29.

Mott

Cline

. Exploring generic drug use behavior: the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution, National Center for Biotechnology Information, U.S. National Library of Medicine, 2002.

30.

Allenet

Barry

. Opinion and behaviour of pharmacists towards the substitution of branded drugs by generic drugs: survey of 1,000 French community pharmacists, Pharm World Sci 2003; 25(5): 197–202.

31.

Gaither

Nadkarni

Mott

, et al. Should I stay or should I go? The influence of individual and organizational factors on pharmacists' future work plans. J Am Pharm Assoc. 47(2):165–173.

32.

Al-Gadadi

Hassali

Shafie

. A pilot survey on perceptions and knowledge of generic medicines among consumers in Penang, Malaysia. Pharm Pract 2008; 6 (2): 93–97.

33.

Rizzo

Zackhauser

. The Competitive and Pricing Consequences of Generic Substitution. Ksg Home, 2008. http://ksghome.harvard.edu/∼rzeckhauser.academic.ksg

34.

Jena . Marketing Strategies Work by Different Pharmaceutical Companies, 2009. http://www.indianmba.com/Faculty_Column/FC1044/fc1044.html

35.

Sanisphere

. Provides Market Intelligence Services to the Pharmaceutical Industry in Emerging Markets, 2012.